Relapse prevention in schizophrenia - Authors' reply
- PMID: 35305748
- DOI: 10.1016/S2215-0366(22)00072-4
Relapse prevention in schizophrenia - Authors' reply
Conflict of interest statement
In the past 3 years, SL has received honoraria for service as a consultant or adviser for Alkermes, Angelini, Gedeon Richter, Lundbeck, Recordati, ROVI, Sandoz, and TEVA; and for lectures from Angelini, Eisai, Gedeon Richter, Janssen, Johnson & Johnson, Lundbeck, Merck Sharp & Dohme, Otsuka, Recordati, SanofiAventis, Sunovion, and Medichem. The other authors declare no competing interests.
Comment on
-
Psychosocial and psychological interventions for relapse prevention in schizophrenia: a systematic review and network meta-analysis.Lancet Psychiatry. 2021 Nov;8(11):969-980. doi: 10.1016/S2215-0366(21)00243-1. Epub 2021 Oct 12. Lancet Psychiatry. 2021. PMID: 34653393
-
Relapse prevention in schizophrenia.Lancet Psychiatry. 2022 Apr;9(4):e13. doi: 10.1016/S2215-0366(21)00501-0. Lancet Psychiatry. 2022. PMID: 35305747 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
